Valo and nference began a multi-year collaboration linking Opal with nference's agentic AI platform and federated patient data.

Valo wanted better clinical data access to shorten target identification and development timelines. It gains access to nference's platform and federated network of de-identified academic medical centre data, which the page puts at over 40 million patient journeys. No outcomes are quantified.

Valo Health is an AI drug discovery company whose Opal platform combines real-world patient data and computation to find targets and small molecules for partners.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.